文献速递流行病学与生物统计临床试验与 GCP

随机试验中超说明书用药与获批药物治疗效果无一致优劣

Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials.
PubMed 文献 · J Clin Epidemiol · 2017-11-13

该系统评价检索至2015年5月,纳入25项治疗比较、153项随机对照试验和24592例患者,比较超说明书用药与获批药物的头对头效果。总体超说明书用药更有利(ssOR 0.72;95%CI 0.54-0.95),但仅24%比较达统计学显著,异质性I²=43%。

要点

  • 超说明书与获批药物头对头比较的25项治疗比较中,仅6项(24%)效果差异达统计学显著。
  • 总体汇总超说明书用药更有利(ssOR 0.72;95%CI 0.54-0.95),异质性I²=43%。
  • 患者相关结局分析中24%(6/25)比较达统计学显著,ssOR 0.74(95%CI 0.56-0.98;I²=60%)。

核心结论

  • 批准状态不能可靠指示在超说明书与获批使用头对头比较的临床试验证据情境下哪种药物更有利。
  • 不考虑超说明书用药的药物有效性评估可能提供不完整信息。
  • 资助、政策、报销和治疗决策应基于证据并考虑全部可用治疗选择。

研究设计与样本

  • 系统评价,检索PubMed、MEDLINE、PubMed Health和Cochrane Library截至2015年5月,纳入比较超说明书与获批药物头对头的随机临床试验的Meta分析。
  • 纳入25项治疗比较,共153项随机对照试验和24592例患者。

主要发现

  • 25项比较中6项(24%)超说明书药物显著优效(5/25)或劣效(1/25)于获批治疗。
  • 总体超说明书药物较获批治疗更有利(ssOR 0.72;95%CI 0.54-0.95),比较间存在显著统计学异质性(I²=43%)。
  • 患者相关结局分析类似:24%(6/25)比较达统计学显著差异,ssOR 0.74(95%CI 0.56-0.98;I²=60%)。
  • 系统评价主要结局分析(n=22项比较)异质性较低且总体无统计学显著差异(ssOR 0.85;95%CI 0.67-1.06;I²=0%)。

关键数值与推荐

  • 总体汇总比值比ssOR 0.72(95%CI 0.54-0.95)。
  • 患者相关结局ssOR 0.74(95%CI 0.56-0.98;I²=60%)。
  • 系统评价主要结局ssOR 0.85(95%CI 0.67-1.06;I²=0%)。

临床怎么用

  • 批准状态不能可靠指示在超说明书与获批使用头对头比较的临床试验证据情境下哪种药物更有利。
  • 资助、政策、报销和治疗决策应基于证据并考虑全部可用治疗选择。

局限性

  • 比较间存在显著统计学异质性(I²=43%)。
  • 患者相关结局分析存在显著统计学异质性(I²=60%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Off-label drug use is highly prevalent but controversial and often discouraged assuming generally inferior medical effects associated with off-label use. STUDY DESIGN AND SETTING: We searched PubMed, MEDLINE, PubMed Health, and the Cochrane Library up to May 2015 for systematic reviews including meta-analyses of randomized clinical trials (RCTs) comparing off-label and approved drugs head-to-head in any population and on any medical outcome. We combined the comparative effects in meta-analyses providing summary odds ratios (sOR) for each treatment comparison and outcome, and then calculated an overall summary of the sOR across all comparisons (ssOR). RESULTS: We included 25 treatment comparisons with 153 RCTs and 24,592 patients. In six of 25 comparisons (24%), off-label drugs were significantly superior (five of 25) or inferior (one of 25) to approved treatments. There was substantial statistical heterogeneity across comparisons (I2 = 43%). Overall, off-label drugs were more favorable than approved treatments (ssOR 0.72; 95% CI = 0.54-0.95). Analyses of patient-relevant outcomes were similar (statistical significant differences in 24% (six of 25); ssOR 0.74; 95% CI = 0.56-0.98; I2 = 60%). Analyses of primary outcomes of the systematic reviews (n = 22 comparisons) indicated less heterogeneity and no statistically significant difference overall (ssOR 0.85; 95% CI = 0.67-1.06; I2 = 0%). CONCLUSION: Approval status does not reliably indicate which drugs are more favorable in situations with clinical trial evidence comparing off-label with approved use. Drug effectiveness assessments without considering off-label use may provide incomplete information. To ensure that patients receive the best available care, funding, policy, reimbursement, and treatment decisions should be evidence based considering the entire spectrum of available therapeutic choices.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Ladanie A, Ioannidis JPA, Stafford RS, et al. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2017. PMID: 29146289. doi:10.1016/j.jclinepi.2017.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。